Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2013 September ; 22(9): 1529–1537. doi:
10.1158/1055-9965.EPI-13-0414.

Long-term statin use and risk of ductal and lobular breast cancer among women 55-74 years of age

Jean A. McDougall¹, Kathleen E. Malone¹, Janet R. Daling¹, Kara L. Cushing-Haugen¹,
Peggy L. Porter^{1,2}, and Christopher I. Li¹

¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA

²Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA

Abstract

Background—Mechanistic studies largely support the chemopreventive potential of statins. However, results of epidemiologic studies investigating statin use and breast cancer risk have been inconsistent and lacked the ability to evaluate long-term statin use.

Materials and Methods—We utilized data from a population-based case-control study of breast cancer conducted in the Seattle-Puget Sound region to investigate the relationship between long-term statin use and breast cancer risk. 916 invasive ductal carcinoma (IDC) and 1,068 invasive lobular carcinoma (ILC) cases 55-74 years of age diagnosed between 2000 and 2008 were compared to 902 control women. All participants were interviewed in-person and data on hypercholesterolemia and all episodes of lipid lowering medication use were collected through a structured questionnaire. We assessed the relationship between statin use and IDC and ILC risk using polytomous logistic regression.

Results—Current users of statins for 10 years or longer had a 1.83-fold increased risk of IDC [95% confidence interval (CI): 1.14-2.93] and a 1.97-fold increased risk of ILC (95% CI: 1.25-3.12) compared to never users of statins. Among women diagnosed with hypercholesterolemia, current users of statins for 10 years or longer had more than double the risk of both IDC [odds ratio (OR): 2.04, 95% CI: 1.17-3.57] and ILC (OR: 2.43, 95% CI: 1.40-4.21) compared to never users.

Conclusion—In this contemporary population-based case-control study long-term use of statins was associated with increased risks of both IDC and ILC.

Impact—Additional studies with similarly high frequencies of statin use for various durations are needed to confirm this novel finding.

Introduction

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors, or statins, are a highly effective therapeutic class of drugs used to lower lipids for both primary and secondary prevention of coronary heart disease. The use of statins has increased considerably since their introduction in the United States in 1987. Approximately a quarter of all United States women over the age of 45 report current use of one of the seven different statin drugs on the market today (1).

Corresponding author: Jean A. McDougall, address: 1100 Fairview Ave. N., M4-C308, Seattle, WA 98109, jamcdoug@fhcrc.org, phone: 206-667-5623; fax: 206-667-5948.

The authors of this manuscript have no potential conflicts of interests to disclose.

Evidence from previous epidemiologic studies investigating the use of statins and risk of developing breast cancer is inconsistent, with some studies reporting an increased risk (2-11), some reporting a decreased risk (12-16), and still others reporting no association (17-23). Early studies in rodents demonstrated a carcinogenic potential of statins (24). However, in *in vitro* breast cancer models statins have been shown to inhibit cell proliferation and induce apoptosis (25-27). Meta-analyses have evaluated the conflicting evidence and provided summary estimates of the association between statin use and breast cancer. The meta-analysis by Bonovas, et al. included seven randomized trials and nine observational studies published prior to 2005, and it reported a relative risk (RR) of 1.02 (95% CI: 0.89-1.18) for the association between statin use and breast cancer (28). Published in 2012, Undela, et al. included 24 observational studies and similarly found no evidence of an association between statin use and breast cancer risk (RR = 0.99, 95% CI: 0.94-1.04) (29).

Despite extensive prior research on statin use and breast cancer risk, some important questions remain unanswered. Given the increase in statin use over the past few decades, and that these medications are commonly prescribed for chronic, essentially lifetime use, the studies published to date have had limited ability to evaluate the impact of long durations of current statin use. Of the studies published since 2005, in the NHS cohort only 1.0% of women had currently used statins for 4 years or longer (15), in the WHI cohort only 2.5% had used statins for 3 years or longer (14), and in a large case-control study only 2.7% of controls were current statin users for 5 years or longer (20). Rates of use were highest in the most recently published study based on the Cancer Prevention Study II Nutrition Cohort, where 6.8% of women were current statin users for 5 years or longer (16). Given the frequency with which statins are used and the extended duration women are prescribed them, characterizing the relationship between long-term statin use and breast cancer risk is of clinical and public health importance. In addition, further investigation is needed regarding the impact of statin use on different types of breast cancer. We evaluated these questions using data from a recently completed large-scale population-based case-control study of postmenopausal breast cancer where use of statins was more frequent compared to populations included in prior published studies.

Materials and Methods

We conducted a large population-based case-control study of the two most common histologic subtypes of breast cancer, invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), among women 55 to 74 years of age living in the three county Seattle-Puget Sound metropolitan area (King, Pierce, and Snohomish counties). In the United States, an estimated 70% of all invasive breast cancers diagnosed among postmenopausal women are ductal and approximately 20% are lobular (30). This study was funded in two continuous phases, and data from the first phase based on cases enrolled from January 2000 to March 2004 were published previously (31).

Selection of cases and controls

Breast cancer cases with no prior history of *in situ* or invasive breast cancer, diagnosed between January 2000 and December 2008 while residing in King, Pierce, or Snohomish county were identified through the Cancer Surveillance System (CSS), the population-based tumor registry that serves western Washington state and participates in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. The three counties included in this analysis are among the 13 counties that comprise the Seattle-Puget Sound SEER site. All women diagnosed with an invasive breast cancer with a lobular component based on ICD-O codes 8520, 8522, and 8524 assigned by CSS were potentially eligible as lobular cases. The pathology reports of all of these cases were then centrally

reviewed to confirm eligibility and re-categorize histology groupings as necessary. Given the greater frequency of IDC, an age-matched sample of ~25% IDC cases was selected for recruitment. IDC cases were frequency matched to the ILC case group by 5-year age group. Since controls were ascertained via random digit dialing of landline home telephone numbers, to be eligible all cases were also required to have a landline home telephone. Of the 2,495 eligible cases identified, 1,984 (80%) were interviewed, including 1,068 ILC and 916 IDC cases, 424 (17%) refused and 75 (3%) were deceased.

We used the Mitofsky-Waksberg (32) method of random digit dialing to identify potential controls from the general population of female residents of King, Pierce, and Snohomish counties. Controls were frequency matched within 5-year age groups and county of residence to the cases using one-step recruitment. Of the 1,313 eligible controls identified, 902 (69%) were interviewed and 411(31%) refused.

The reference date used for each woman with breast cancer was her diagnosis date. Control reference dates were assigned to reflect the expected distribution of reference dates among the cases. Data collection was limited to exposures that occurred before each participant's reference date.

Data Collection

The study protocol was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board, and written informed consent was obtained from all study subjects. In addition to basic information on breast cancer diagnosis, we obtained information on tumor characteristics from CSS and from a centralized review of pathology reports. This includes data on estrogen receptor (ER), progesterone receptor (PR), and HER2-neu (HER2) status, and tumor stage, size, and nodal status.

Cases and controls were interviewed in-person. Through a series of structured questions, detailed histories of hypercholesterolemia and all episodes of lipid lowering medication use, including beginning and ending dates, drug name, dose, route of administration, and pattern of use (number of days per month) were obtained. Study participants were also asked to show bottles of all prescription medications they were currently taking, including lipid lowering drugs, to their study interviewer who then directly transcribed data from these bottles onto our data collection form. To enhance recall of past use, a photo book containing pictures of pills and packages of commonly used lipid lowering medications was used along with a show card listing the brand and generic names of each of these medications. Additionally, all participants were queried about various known or suspected breast cancer risk factors including pertinent aspects of their reproductive, medical, breast cancer screening, and family histories, as well as information about their body size and lifestyle habits. Our questioning was limited to exposures that occurred before each participant's reference date. Women were asked if they had ever smoked, drank alcoholic beverages, used a specific medication, been diagnosed with a specific condition, or ever had a mammogram; for cumulative exposure variables patterns of use from the time of first exposure through the reference date were ascertained in the interview.

Statistical Analysis

Women who never used any type of lipid lowering medication served as the reference category. Our main analysis focused on duration and recency of statin use where current users were those who ever used these medications for 6 months or longer and were currently using them within six months of their reference date. Former users were ever users of these medications for 6 months or longer who last used them more than 6 months prior to their reference date. Short-term users were women who used these medications for less than six

months regardless of their recency of use. Analyses also considered risk associated with each individual statin as well as when grouped as lipophilic (atorvastatin, simvastatin, lovastatin, fluvastatin, and cerivastatin) or hydrophilic (pravastatin, and rosuvastatin) statins. Finally, an analysis restricting the sample to the 273 controls, 286 IDC and 320 ILC cases with a history of high cholesterol was conducted to investigate the existence and magnitude of potential biases due to the selection of healthy controls and to confounding by indication.

We used polytomous logistic regression to calculate odds ratios (ORs) and their associated 95% confidence intervals (CIs) to compare IDC and ILC cases to controls. Given the design of this study and its random sampling of IDC cases and exclusion of other histologic subtypes of breast cancer, risk estimates for breast cancer overall could not be calculated. Pearson's chi-squared statistic was calculated modeling categories of years of statin use as a grouped linear variable to test for a trend in duration. All analyses were conducted using Stata/SE version 11.2 (StataCorp LP, College Station, TX). All models were adjusted for age (five year categories), reference year (continuous), and county, since controls were frequency matched to cases on these factors. Several potential confounders and effect modifiers of the relationship between statin use and breast cancer were assessed, including: education, household income, race/ethnicity, use of menopausal hormone therapy, mammography screening history, type of menopause, first degree family history of breast cancer, body mass index one year prior to reference date, presence of diabetes, parity, alcohol consumption, and smoking history (as grouped in table 1). Only use of menopausal hormone therapy changed our risk estimates by more than 10% when added to the model, and so, only it was added as a covariate to our final statistical models. Excluded from all analyses were the 25 controls, 25 IDC cases, and 32 ILC cases missing data on either use of lipid lowering medications and/or menopausal hormone therapy use leaving a final analytic sample size of 877 controls, 891 IDC cases, and 1,036 ILC cases. In addition, none of the covariates were found to be a statistically significant effect modifier based on likelihood ratio testing including body mass index (all p-values for interaction were >0.05). To quantify differences in risk according to use of menopausal hormone therapy and mammography screening history we also assessed risks stratified by these two factors. In addition, we assessed whether or not risk estimates differed among women with invasive lobular (ICD-O codes 8520 and 8524) versus invasive ductal-lobular (ICD-O code 8522) carcinomas. No appreciable differences in the magnitudes of risk were observed when the analysis was stratified in this way and none of the p-values comparing lobular versus ductal-lobular risk estimates were statistically significant. Thus lobular and ductal-lobular tumors were grouped together in all analyses. Lastly, we conducted analyses stratified according to estrogen receptor (ER) status in three groupings: ER+ IDC, ER- IDC, and ER+ ILC. Given that fewer than 4% of our ILC cases were ER- we could not evaluate risk among ER- ILC cases.

Results

Controls, IDC cases, and ILC cases had similar distributions of age, household income, history of hypercholesterolemia, and history of heart disease (Table 1). Compared to controls and IDC cases, ILC cases were somewhat more likely to be non-Hispanic white, to have completed college, to consume 1 alcoholic beverage per day, to have a body mass index <25 kg/m², and to be current users of combined estrogen and progestin menopausal hormone therapy. IDC and ILC cases were more likely than controls to have a first-degree family history of breast cancer; however, mammography screening history was similar across all groups.

Compared to never users, women who ever used statins did not have an increased risk of IDC (OR: 1.16, 95% CI: 0.92-1.47) (Table 2). There was a modest suggestion of an increased risk of ILC (OR: 1.22, 95% CI: 0.98-1.53) comparing women who ever used

statins to never users. However, women using statins for 10 years had a 72% higher risk of IDC (95% CI: 1.10-2.71) and an 82% higher risk of ILC (95% CI: 1.17-2.82), though neither p-value for linear trend was statistically significant. When evaluated by recency, current long-term (10 years) statin users had an 83% higher risk of IDC (95% CI: 1.14-2.93, p for trend=0.043) and a 97% higher risk of ILC (OR: 1.97, 95% CI: 1.25-3.12, p for trend=0.021) than never users. When analyses were restricted to the 273 controls, 286 IDC cases, and 320 ILC cases with a history of high cholesterol, the associations observed were slightly greater in magnitude to those observed in our overall analyses. Current use of any statin for at least 6 months was associated with a 41% increased risk of IDC (95% CI: 0.95-2.08) and a 63% increased risk of ILC (95% CI: 1.11-2.41). Again, this increased risk was strongest among long-term statin users who had more than double the risk of both IDC (OR: 2.04, 95% CI: 1.17-3.57, p for trend=0.025) and ILC (OR: 2.43, 95% CI: 1.40-4.21, p for trend=0.006).

The vast majority (88%) of statin users in this population used lipophilic statins. Current use of lipophilic statins was not associated with either IDC (OR 1.13, 95% CI 0.88-1.45) or ILC (OR 1.21, 95% CI 0.95-1.54) (Table 3). However, current users of lipophilic statins for 10 years had a 74% increased risk of IDC (95% CI: 1.05-2.86) and a 68% increased risk of ILC (95% CI: 1.02-2.76) compared to never users. The two most commonly used statins in this population were atorvastatin and simvastatin. Current use of atorvastatin for 10 years was associated with elevated risks of both IDC and ILC but while both of these risk estimates were within the limits of chance, the trend with respect to IDC was statistically significant (p=0.048). There were no clear associations between simvastatin use and IDC or ILC risk.

Stratifying by ER status there was evidence that while current statin use for 10 years was associated with two-fold increases in risk of ER+ IDC (OR: 1.97, 95% CI: 1.21-3.20, p for trend=0.035) and ER+ ILC (OR: 2.00, 95% CI: 1.26-3.17, p for trend=0.023), it was associated with a more modest non-statistically significant elevated risk of ER- IDC (OR: 1.33; 95% CI: 0.53-3.31) (Table 4).

Discussion

In this population-based case-control study 10 years of statin use was associated with an increased risk of both IDC and ILC. Our estimate of a 26% increased risk of IDC among women using statins for 5-10 years is consistent with estimates from three previous studies reporting relative effects between 10% and 30% associated with 5 years of statin use (7, 16, 20). However, our estimate differs from studies reporting a decreased risk of breast cancer associated with 4 years of statin use (3, 22). Consistent with previous studies we did not observe evidence of associations between shorter durations of statin use and breast cancer risk. Only one prior study has reported data for statin use of 10 years and found no association between long-term statin use and breast cancer risk (OR 0.8, 95% CI: 0.5 – 1.4) (20). We observed that risks were highest among long-term current users suggesting that statins may act as promoters of breast carcinogenesis.

This study differed from previous studies in its ability to investigate the association between statin use and breast cancer separately by histologic subtype and estrogen receptor (ER) status. Among long-term statin users, we saw substantially increased risks of both ER+ IDC and ER+ ILC, but no increased risk of ER- IDC. Given the relatively small number of ER- cases in our study and the resulting uncertainty in our estimates, it is not clear whether the association between long-term statin use and breast cancer risk differs by ER status. While studies of the WHI and NHS cohorts found null associations for use of statins and breast cancer for both ER+ and ER- tumors, neither study had data on long-term statin users (14, 15). If in fact statins are only associated with ER+ breast cancer this would suggest that

statins may be exerting a carcinogenic effect through a hormonally driven pathway. However, the biology underlying an association between statin use and breast cancer risk is uncertain. All statins inhibit HMG-CoA reductase at the rate limiting step of the mevalonate pathway, an intricate biochemical pathway required for the production of cholesterol, isoprenoids, dolichol, ubiquinone and isopentenyladine (33). Laboratory studies have investigated how disrupting the mevalonate pathway may lead to carcinogenesis and have discovered both pro and anti-cancer effects of statins (34). However, our results call into question whether the anti-carcinogenic properties of statins observed in animal models apply to the long-term effects of disrupting the mevalonate pathway in humans. Our finding of an increased risk only among current long-term statin users suggests that the chronic dysregulation of the mevalonate pathway and/or long-term lowering of serum cholesterol may contribute to breast carcinogenesis. This finding does not rule out the possibility that shorter term statin use may have no effect or possibly a transitory protective effect on the development of breast cancer.

Prior studies examining individual statins have not found increased risks of breast cancer associated with use of any individual statin, with the exception of the randomized trial of pravastatin, a hydrophilic statin, that reported a 12-fold increased risk of breast cancer (12 cases in the pravastatin arm compared to 1 case in the control arm) (35). However, other trials of pravastatin found no increase in breast cancer in the treatment arm (36, 37). In the WHI cohort while use of hydrophilic statins was not related to breast cancer risk, an 18% ($p = 0.02$) lower breast cancer incidence was observed among users of lipophilic statins (simvastatin, lovastatin or fluvastatin) compared to statin nonusers (14). However, it should be noted that two thirds of statin users in the WHI cohort had used statins for <3 years. In contrast, a recent large case-control study found no evidence of an association between lipophilic statins and breast cancer (23). Our finding of an increased risk of breast cancer among long-term, primarily lipophilic, statin users does not support the use of statins for breast cancer prevention and suggests that the risk of breast cancer may be elevated for both users of lipophilic and hydrophilic statins.

It is also important to acknowledge the potential limitations of this study. Given its design, recall bias is a potential concern. However, our study interviewers used showcards with pictures of medications to enhance recall and had all participants bring all of their current medications to the interview to minimize misclassification. Furthermore, a validation study comparing self-reported statin use to data from pharmacy records conducted among women aged 65-79 years from Washington State found no significant differences in recall of recent statin use between breast cancer cases (sensitivity 83%, 95% CI: 64, 93) and controls (sensitivity 93%, 95% CI: 69, 99) and suggested that any differential misclassification would likely result in a spuriously low proportion of statin users among breast cancer cases biasing the OR for the association between statin use and breast cancer towards the null, given that cases were less likely to be correctly classified as statin users (38). Selection bias is also a possible explanation for the observation that IDC and ILC cases were more likely to be long term statin users than controls. It is possible that the controls available through RDD who agreed to participate in our study were healthier than the general population, resulting in a spuriously low proportion of statin users in our controls. Our finding that controls, IDC cases and ILC cases all had similar proportions of women with a history of high cholesterol and heart disease as well as similar mammography screening history does not suggest that the controls were exceptionally healthy. We also did not observe differences in the magnitude of the association between statin use and breast cancer when analyses were stratified by mammography screening history, suggesting that the observed results are not explained by a higher frequency of screening in among statin users. It is possible that our finding of an increased risk of breast cancer among long-term statin users is attributable to differences in characteristics of long-term statin users rather than to statin use itself.

However, our finding of a greater than 2-fold increased risk of breast cancer among current long-term statin users in analyses restricted to study participants reporting a history of high cholesterol is evidence that confounding by indication does not account for the excess of breast cancer cases among statin users.

The finding that current, long-term use of statins may double the risk of both ductal and lobular breast cancer warrants further study. This is the first study with the power to examine long-term effects of statins on breast cancer risk. In contrast to the NHS and WHI studies where the prevalence of statin use was 2.6% and 7.5% respectively, 25% of controls in our study population were current statin users and 18% of those had used statins for 10 years. As more women are taking statins and for longer durations than were previously available for study it is possible that we will observe effects of long-term statin use that prior studies could not detect. Confirmation of these results in other studies is necessary before any changes in clinical practice would be warranted.

Acknowledgments

research support: This research was funded by a grant from the National Cancer Institute R01 CA 85913. This publication was supported by grant number T32 CA09168 from the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCI, NIH.

References

1. Control CfD. National Health and Nutrition Examination Survey. Chartbook: Centers for Disease Control; 2010. Data table for Figure 17. Statin drug use in the past 30 days among adults 45 years of age and over, by sex and age: United States, 1988–1994, 1999–2002, and 2005–2008.
2. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch Intern Med. 1993; 153(9):1079–87. Epub 1993/05/10. [PubMed: 8481075]
3. Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol. 2003; 56(3):280–5. Epub 2003/05/03. [PubMed: 12725884]
4. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005; 114(4):643–7. Epub 2004/12/04. 10.1002/ijc.20758 [PubMed: 15578694]
5. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90(3):635–7. Epub 2004/02/05. 10.1038/sj.bjc.6601566 [PubMed: 14760377]
6. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004; 22(12):2388–94. Epub 2004/06/16. 10.1200/JCO.2004.02.027 [PubMed: 15197200]
7. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev. 2007; 16(3):416–21. Epub 2007/03/21. 10.1158/1055-9965.EPI-06-0737 [PubMed: 17372235]
8. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology. 2002; 13(3):262–7. Epub 2002/04/20. [PubMed: 11964926]
9. Eaton M, Eklof J, Beal JR, Sahmoun AE. Statins and breast cancer in postmenopausal women without hormone therapy. Anticancer Res. 2009; 29(12):5143–8. Epub 2010/01/02. [PubMed: 20044629]
10. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol. 2009; 67(1):99–109. Epub 2008/11/14. 10.1111/j.1365-2125.2008.03308.x [PubMed: 19006546]
11. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010; 340:c2197. Epub 2010/05/22. 10.1136/bmj.c2197 [PubMed: 20488911]

12. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. *Arch Intern Med.* 2000; 160(15):2363–8. Epub 2000/08/06. [PubMed: 10927735]
13. Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. *J Womens Health (Larchmt).* 2003; 12(8):749–56. Epub 2003/11/01. 10.1089/154099903322447710 [PubMed: 14588125]
14. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. *J Natl Cancer Inst.* 2006; 98(10):700–7. Epub 2006/05/18. 10.1093/jnci/djj188 [PubMed: 16705124]
15. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. *Arch Intern Med.* 2005; 165(19):2264–71. Epub 2005/10/26. 10.1001/archinte.165.19.2264 [PubMed: 16246993]
16. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. *Cancer Res.* 2011; 71(5):1763–71. Epub 2011/02/24. 10.1158/0008-5472.CAN-10-2953 [PubMed: 21343395]
17. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. *Cancer.* 2004; 100(11):2308–16. Epub 2004/05/26. 10.1002/cncr.20271 [PubMed: 15160333]
18. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. *Pharmacoepidemiol Drug Saf.* 2008; 17(1):27–36. Epub 2007/10/19. 10.1002/pds.1507 [PubMed: 17944002]
19. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, et al. Incidence of cancer and statin usage--record linkage study. *Int J Cancer.* 2010; 126(1):279–84. Epub 2009/09/10. 10.1002/ijc.24536 [PubMed: 19739258]
20. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM. Statin use and risk of breast cancer. *Cancer.* 2008; 112(1):27–33. Epub 2007/11/17. 10.1002/cncr.23129 [PubMed: 18008366]
21. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. *Circulation.* 2007; 115(1):27–33. Epub 2006/12/21. 10.1161/CIRCULATIONAHA.106.650176 [PubMed: 17179016]
22. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. *BMC Cancer.* 2011; 11:409. Epub 2011/09/29. 10.1186/1471-2407-11-409 [PubMed: 21943022]
23. Woditschka S, Habel LA, Udaltsova N, Friedman GD, Sieh W. Lipophilic statin use and risk of breast cancer subtypes. *Cancer Epidemiol Biomarkers Prev.* 2010; 19(10):2479–87. Epub 2010/08/24. 10.1158/1055-9965.EPI-10-0524 [PubMed: 20729289]
24. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. *JAMA.* 1996; 275(1):55–60. Epub 1996/01/03. [PubMed: 8531288]
25. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. *Proc Natl Acad Sci U S A.* 1999; 96(14):7797–802. Epub 1999/07/08. [PubMed: 10393901]
26. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. *Br J Cancer.* 2002; 87(6):635–44. Epub 2002/09/19. 10.1038/sj.bjc.6600510 [PubMed: 12237774]
27. Seeger H, Wallwiener D, Mueck AO. Statins can inhibit proliferation of human breast cancer cells in vitro. *Exp Clin Endocrinol Diabetes.* 2003; 111(1):47–8. Epub 2003/02/28. 10.1055/s-2003-37501 [PubMed: 12605351]
28. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. *J Clin Oncol.* 2005; 23(34):8606–12. Epub 2005/11/02. 10.1200/JCO.2005.02.7045 [PubMed: 16260694]
29. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. *Breast Cancer Res Treat.* 2012; 135(1):261–9. Epub 2012/07/19. 10.1007/s10549-012-2154-x [PubMed: 22806241]

30. Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. *Cancer Epidemiol Biomarkers Prev.* 2007; 16(12):2773–80. Epub 2007/12/19. 10.1158/1055-9965.EPI-07-0546 [PubMed: 18086787]
31. Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, et al. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. *Cancer Epidemiol Biomarkers Prev.* 2008; 17(1):43–50. Epub 2008/01/18. 10.1158/1055-9965.EPI-07-0558 [PubMed: 18199710]
32. Hartge P, Brinton LA, Rosenthal JF, Cahill JJ, Hoover RN, Waksberg J. Random digit dialing in selecting a population-based control group. *Am J Epidemiol.* 1984; 120(6):825–33. Epub 1984/12/01. [PubMed: 6334439]
33. Clendening JW, Pandya A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. *Proc Natl Acad Sci U S A.* 2010; 107(34):15051–6. Epub 2010/08/11. 10.1073/pnas.0910258107 [PubMed: 20696928]
34. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. *Nat Rev Cancer.* 2005; 5(12):930–42. Epub 2005/12/13. 10.1038/nrc1751 [PubMed: 16341084]
35. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996; 335(14):1001–9. Epub 1996/10/03. 10.1056/NEJM199610033351401 [PubMed: 8801446]
36. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med.* 1998; 339(19):1349–57. Epub 1998/12/05. 10.1056/NEJM199811053391902 [PubMed: 9841303]
37. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA.* 2002; 288(23):2998–3007. Epub 2002/12/20. [PubMed: 12479764]
38. Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. *Am J Epidemiol.* 2004; 159(3):308–17. Epub 2004/01/27. [PubMed: 14742292]

Table 1

Demographic characteristics of the study population

Characteristic	Controls (n = 877)		Ductal Cases (n = 891)		Lobular Cases (n = 1,036)	
	No.	%	No.	%	No.	%
Age at reference date						
55 - 59	252	28.7%	259	29.1%	306	29.5%
60 - 64	230	26.2%	245	27.5%	294	28.4%
65 - 69	222	25.3%	211	23.7%	241	23.3%
70 - 74	173	19.7%	176	19.8%	195	18.8%
Race/ethnicity						
Non-Hispanic White	778	88.9%	804	90.4%	960	92.8%
African American	27	3.1%	22	2.5%	14	1.4%
Asian/Pacific Islander	17	1.9%	35	3.9%	21	2.0%
Native American	24	2.7%	16	1.8%	20	1.9%
Hispanic White	29	3.3%	12	1.3%	20	1.9%
Missing	2		2		1	
Education						
Less than high school	39	4.5%	46	5.2%	62	6.0%
High school graduate	207	23.6%	207	23.3%	365	35.2%
Some college	343	39.2%	331	37.2%	221	21.3%
College degree or higher	287	32.8%	306	34.4%	388	37.5%
Missing	1		1		0	
Annual household income						
< \$20,000	82	10.7%	102	12.9%	100	11.0%
\$20,000 - \$34,999	138	18.0%	129	16.3%	173	19.1%
\$35,000 - \$69,999	285	37.1%	273	34.6%	294	32.5%
\$70,000 - \$89,999	88	11.5%	102	12.9%	132	14.6%
\$90,000	175	22.8%	184	23.3%	207	22.8%
Missing	109		101		130	
Alcohol use						
None	441	50.6%	419	47.4%	480	46.6%
< 1 drink per day	299	34.3%	312	35.3%	345	33.5%

Characteristic	Controls (n = 877)		Ductal Cases (n = 891)		Lobular Cases (n = 1,036)	
	No.	%	No.	%	No.	%
1 drink per day	132	15.1%	153	17.3%	205	19.9%
Missing	5		7		6	
Smoking status						
Never	440	50.2%	445	50.0%	495	47.8%
Former	348	39.7%	342	38.4%	416	40.2%
Current	88	10.0%	103	11.6%	125	12.1%
Missing	1		1		0	
Body mass index, kg/m ²						
< 25	264	30.4%	285	32.0%	367	35.5%
25 - 29.9	300	34.5%	283	31.8%	342	33.1%
30	305	35.1%	322	36.2%	324	31.4%
Missing	8		1		3	
History of high cholesterol						
No	602	68.8%	604	67.9%	713	69.0%
Yes	273	31.2%	286	32.1%	320	31.0%
Missing	2		1		3	
History of heart disease						
No	385	44.0%	406	45.7%	471	45.6%
Yes	490	56.0%	482	54.3%	563	54.4%
Missing	2		3		2	
First degree family history of breast cancer						
No	697	82.2%	654	76.7%	771	76.8%
Yes	151	17.8%	199	23.3%	233	23.2%
Missing	29		38		32	
Mammography screening history						
Less than annual	394	45.1%	409	46.0%	490	47.6%
Annual only	469	53.7%	462	52.0%	521	50.6%
More than annual	11	1.3%	18	2.0%	19	1.9%
Missing	3		2		6	
Hormone therapy use						

Characteristic	Controls (n = 877)		Ductal Cases (n = 891)		Lobular Cases (n = 1,036)	
	No.	%	No.	%	No.	%
Never	249	28.4%	322	36.1%	261	25.2%
Former	310	35.3%	242	27.2%	256	24.7%
Current estrogen only	202	23.0%	162	18.2%	219	21.1%
Current estrogen + progestin	116	13.2%	165	18.5%	300	29.0%

Table 2

Associations between statin use and risk of invasive ductal or lobular breast cancer among women age 50 - 74 overall and among women with a history of high cholesterol

All Study Participants											
	Controls (n = 877)			Ductal cases (n = 891)			Lobular cases (n = 1,036)			OR	95% CI
	No.	%		No.	%	OR	95% CI	No.	%		
Never use	674	77%		664	75%	1.00	reference	782	76%	1.00	reference
Ever use for 6mo	190	22%		206	23%	1.16	0.92 - 1.47	237	23%	1.22	0.98 - 1.53
Duration of ever use											
6mo - <5yrs	104	12%		93	11%	0.93	0.68 - 1.26	122	12%	1.12	0.84 - 1.49
5yrs - <10yrs	50	6%		57	6%	1.26	0.84 - 1.89	51	5%	1.03	0.68 - 1.56
10 yrs	35	4%		53	6%	1.72	1.10 - 2.71	62	6%	1.82	1.17 - 2.82
p-value for trend											
p = 0.173											
Recency of use											
Former use	20	2%		20	2%	1.12	0.59 - 2.13	19	2%	1.02	0.53 - 1.95
Current use	170	19%		184	21%	1.16	0.91 - 1.15	218	21%	1.25	0.98 - 1.57
Duration of current use											
6mo - <5yrs	91	10%		79	9%	0.90	0.65 - 1.24	109	11%	1.13	0.83 - 1.53
5yrs - <10yrs	47	5%		54	6%	1.26	0.83 - 1.91	47	5%	1.00	0.65 - 1.53
10 yrs	31	4%		50	6%	1.83	1.14 - 2.93	60	6%	1.97	1.25 - 3.12
p-value for trend											
p = 0.043											
Study Participants with a History of High Cholesterol											
	Controls (n = 273)			Ductal cases (n = 286)			Lobular cases (n = 320)			OR	95% CI
	No.	%		No.	%	OR	95% CI	No.	%		
Never use	85	31%		71	25%	1.00	Ref	77	24%	1.00	Ref
Ever use for 6mo	175	64%		195	68%	1.42	0.96 - 2.09	227	71%	1.64	1.12 - 2.41
Current use	158	57.9		175	61%	1.41	0.95 - 2.08	208	65%	1.63	1.11 - 2.41
Duration of ever use											
6mo - <5yrs	93	34%		88	31%	1.19	0.77 - 1.84	116	37%	1.55	1.01 - 2.37
5yrs - <10yrs	48	18%		54	19%	1.46	0.87 - 2.44	48	15%	1.31	0.77 - 2.22
10 yrs	33	12%		51	18%	2.04	1.17 - 3.57	61	19%	2.43	1.40 - 4.21

All Study Participants									
Controls (n = 877)			Ductal cases (n = 891)			Lobular cases (n = 1,036)			
No.	%		No.	%		No.	%	OR	95% CI
<i>p-value for trend</i>						<i>p = 0.025</i>			
						<i>p = 0.006</i>			

OR: odds ratio adjusted for reference year, reference age, county of residence, and HRT

Table 3
Relationship between use of statins and breast cancer risk by solubility and for the most commonly used statin medications

Controls (n = 877)				Ductal cases (n = 891)				Lobular cases (n = 1,036)			
	No.	%		No.	%	OR	95% CI	No.	%	OR	95% CI
Never use	674	76.9		664	74.8	1.00	reference	782	75.6	1.00	reference
Hydrophilic statins											
Current use	13	1.5		18	2.0	1.56	0.75 - 3.24	21	2.0	1.65	0.81 - 3.38
Lipophilic statins											
Current use	157	17.9		166	18.7	1.13	0.88 - 1.45	196	18.9	1.21	0.95 - 1.54
6mo - <5yrs	84	9.6		76	8.6	0.95	0.68 - 1.33	104	10.1	1.17	0.86 - 1.61
5yrs - <10yrs	44	5		45	5.1	1.09	0.70 - 1.69	44	4.3	0.96	0.62 - 1.50
10 yrs	28	3.2		43	4.8	1.74	1.05 - 2.86	45	4.4	1.68	1.02 - 2.76
p-value for trend						p = 0.119				p = 0.094	
Atorvastatin											
Current use	77	8.8		93	10.5	1.34	0.96 - 1.85	98	9.5	1.25	0.91 - 1.74
6mo - <5yrs	37	4.2		47	5.3	1.39	0.88 - 2.17	56	5.4	1.46	0.94 - 2.25
5yrs - <10yrs	28	3.2		26	2.9	1.01	0.58 - 1.77	24	2.3	0.85	0.48 - 1.51
10 yrs	12	1.4		20	2.3	1.97	0.94 - 4.11	18	1.7	1.55	0.73 - 3.30
p-value for trend						p = 0.048				p = 0.254	
Simvastatin											
Current use	50	5.7		49	5.5	0.97	0.64 - 1.48	57	5.5	1.05	0.70 - 1.57
6mo - <5yrs	30	3.4		29	3.3	0.93	0.54 - 1.58	35	3.4	1.03	0.62 - 1.72
5yrs - <10yrs	14	1.6		12	1.4	0.94	0.42 - 2.07	13	1.3	0.90	0.41 - 1.96
10 yrs	6	0.7		8	0.9	1.30	0.44 - 3.85	9	0.9	1.49	0.52 - 4.28
p-value for trend						p = 0.729				p = 0.681	

OR: odds ratio adjusted for reference year, reference age, county of residence, and hormone therapy use

Associations between statin use and risk of estrogen receptor (ER) positive or negative breast cancer

OR: odds ratio adjusted for reference year, reference age, county of residence, and hormone therapy use

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2014 September 01.